Tech Transfer Central

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics

Published by CurrentPartnering
Format: PDF
Publication Date: 2020
2,000+ pages

Share:
Twitter Facebook Linkedin Pinterest Email
Price: Starting at $3,495
order button view cart

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics

Comprehensive and up-to-date access to the latest licensing agreements announced in the pharmaceutical, biotechnology, and diagnostic sectors – all details of licensing agreements from 2014 through mid-2020

With this comprehensive 1,000 + page report – plus five appendices – you’ll receive:

  • Trends in licensing dealmaking in the biopharma industry since 2014
  • Analysis of licensing deal structure
  • Case studies of real-life licensing deals
  • Comprehensive listing of licensing deals since 2014
  • Access to licensing contract documents
  • Key financial benchmarks for headline, upfront, milestone and royalty rates
  • The leading licensing deals and most active licensing dealmakers since 2014
  • The leading licensing partnering resources

The new 2020 release of Global Licensing Terms & Agreements In Pharma, Biotech and Diagnostics provides you with unprecedented access to licensing deals and agreements entered into by the world’s leading life science companies

This comprehensive reference provides a listing of all pharma, biotech, and diagnostics licensing deals announced since 2014 – including financial terms plus links to online copies of actual licensing contract documents. This 1,000+ page report will give you critical insight into what you can realistically expect to achieve during your own negotiation.

With Global Licensing Terms & Agreements in Pharma, Biotech and Diagnostics, you’ll benefit from:

  • In-depth understanding of licensing partnering deal trends from 2014 through mid-2020
  • Analysis of the structure of licensing agreements with numerous real life case studies
  • Comprehensive listing of all licensing deals since 2014, including deal terms and value
  • Access to actual licensing contracts entered into by the world’s life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into terms included in a licensing agreement, together with real world clause examples
  • In-depth understanding of key deal terms companies have agreed to in previous deals

This unique resource also includes numerous tables and figures that illustrate the trends and activities in biopharma dealmaking since 2014.

Plus All available deals and contracts are listed by: Company A-Z, Headline Value, Therapeutic Area, and Technology Type.

And, each deal title links to an online version of the actual deal record and contract documents (where available), providing easy access to each contract document on demand. Having access to actual contract agreements allows more detailed assessment including:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestones align with clinical stage development phases?
  • How are sales and payments audited?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
Detailed DescriptionBenefitsTable of Contents

The report provides a detailed understand and analysis of how and why companies enter licensing deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all licensing deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading licensing deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 50 most active biopharma companies in licensing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a comprehensive review of licensing financials for deals announced since 2014, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

Chapter 7 provides a comprehensive and detailed review of licensing deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in licensing deal making since 2014.

In addition, a comprehensive appendix is provided organized by licensing company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 provides the reader with the following key benefits:

  • In-depth understanding of licensing partnering deal trends since 2014
  • Analysis of the structure of licensing agreements with numerous real life case studies
  • Comprehensive listing of over 4,500 licensing deals since 2014, together with deal terms, value and press release
  • Comprehensive access to actual licensing contracts entered into by the world’s life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a licensing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.        

Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 includes:

  • Trends in licensing dealmaking in the biopharma industry since 2014
  • Analysis of licensing deal structure
  • Case studies of real-life licensing deals
  • Comprehensive listing of over 4,500 licensing deals since 2014
  • Access to licensing contract documents
  • Key financial bnchmarks for headline, upfront, milestone and royalty rates
  • The leading licensing deals by value since 2014
  • Most active licensing dealmakers since 2014
  • The leading licensing partnering resources

In Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in licensing deal making

2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2014
2.6.1. Licensing deal making by year since 2014
2.6.2. Licensing deal making by phase of development since 2014
2.6.3. Licensing deal making by industry sector since 2014
2.6.4. Licensing deal making by therapy area since 2014
2.6.5. Licensing deal making by technology type since 2014
2.6.6. Licensing deal making by most active company since 2014
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 – Overview of licensing deal structure

3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta – Nerviano Medical Sciences
3.3.1.b. Case study 2: Sanofi – Pozen
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories – Trevena
3.4.2.b. Case study 6: Abbvie – Receptos

Chapter 4 – Leading licensing deals

4.1. Introduction
4.2. Top licensing deals by value

Chapter 5 – Top 25 most active licensing dealmakers

5.1. Introduction
5.2. Top 25 most active licensing dealmakers

Chapter 6 – Licensing deal term financials

6.1. Introduction
6.2. Licensing partnering headline values
6.3. Licensing deal upfront payments
6.4. Licensing deal milestone payments
6.5. Licensing royalty rates

Chapter 7 – Licensing contract directory since 2014

7.1. Introduction
7.2. Licensing deals with contracts since 2014

Appendices

Appendix 1 – Licensing dealmaking by companies A-Z
Appendix 2 – Licensing dealmaking by industry sector
Appendix 3 – Licensing dealmaking by stage of development
Appendix 4 – Licensing dealmaking by therapy area
Appendix 5 – Licensing dealmaking by technology type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements since 2014
Figure 5: Licensing deals signed at each phase of development since 2014
Figure 6: Licensing deals by industry sector since 2014
Figure 7: Licensing deals by therapy area since 2014
Figure 8: Licensing deals by technology type since 2014
Figure 9: Top 25 most active licensing dealmakers sinnce 2014
Figure 10: Licensing agreements – what should a contract include?
Figure 11: Components of the licensing deal structure
Figure 12: Top licensing deals by value since 2014
Figure 13: Most active licensing dealmakers since 2014
Figure 14: Licensing deals with a headline value
Figure 15: Licensing deals with an upfront value
Figure 16: Licensing deals with a milestone value
Figure 17: Licensing deals with a royalty rate value

order button
view cart


Click here for a printable order form